TOG Review (RCOG Journal)
MRCOG Part 2
Core Surgical Skills
Perioperative management of women on oral anticoagulants and antiplatelet agents
Key Statistics
- 10–15% — AF patients needing temporary interruption for elective surgery
- ≥7 days — Recommended preop assessment before surgery
- 5 days — Warfarin stopped preop, all bleeding risks
Don't-miss facts
-
Warfarin: stop 5 days preop (all risk levels); bridge with treatment-dose LMWH only if high thrombotic risk (Box 1)
-
Bridging LMWH restart delayed ≥48h after high bleeding-risk surgery; warfarin restart evening/next day if haemostasis adequate
-
Apixaban/rivaroxaban/edoxaban share one stop schedule by CrCl; dabigatran stratified separately (higher renal clearance, 80%)
-
Aspirin monotherapy – continue for gynae procedures; dual antiplatelet post-ACS/stent – postpone surgery ≥6 months if possible
-
Emergency warfarin reversal: 5 mg IV phytomenadione (6–8h available) or 25–50 u/kg 4-factor PCC (cannot wait)
-
Idarucizumab reverses dabigatran; no reversal agent for clopidogrel (effect lasts 7–9 days) — use tranexamic acid ± donor platelets
-
Neuraxial block: aspirin/NSAIDs need not stop; ADP antagonists stopped 7 days prior (treat as high bleeding risk)
-
Box 2 bleeding risk: no risk = smear/exam/swabs; minor = LLETZ, hysteroscopy, Pipelle, polypectomy, vulval/cervical biopsy; major = all day-case/inpatient surgery
Quick agent snapshot
Aspirin: continue Warfarin: stop 5d Apixaban/rivaroxaban/edoxaban: stop 24–72h by CrCl
Dabigatran: stop 24–96h by CrCl Clopidogrel: 7d if high risk
Abbreviation Key
- DOAC — direct oral anticoagulant (previously novel oral anticoagulant)
- ADP — adenosine diphosphate
- NIC — net ingredient cost
- INR — international normalised ratio
- LLETZ — large loop excision of the transformation zone
- LMWH — low-molecular-weight heparin
- NSAID — nonsteroidal anti-inflammatory drug
- VTE — venous thromboembolism
- PCC — prothrombin complex concentrate
- TIA — transient ischaemic attack
Source: Goh E et al. Perioperative management of women on oral anticoagulants and antiplatelet agents undergoing gynaecological procedures. The Obstetrician & Gynaecologist 2022;22:131–136. doi:10.1111/tog.12650
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).